CRSP
CRISPR Therapeutics AG
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
+8/100
Last price
54.00
▼ 3.34 (5.82%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
57.70
Prev close
57.34
Day high
60.68
Day low
53.74
Volume
2.62M
Market cap
$5.22B
P/E (TTM)
—
52W range
44.12 – 78.48
Day trading desk
Gap from prior close
+0.63%
Prior close 57.34
VWAP
55.43
-2.58% from price
Relative volume
1.50×
Unusually busy
Session range
14.25%
53.74 – 61.40
Position in range
3%
Near session low
ATR (14D)
3.56
6.59% of price
Prior day high
57.46
PDH
Prior day low
54.01
PDL
Bid / ask spread
—
Quote not published
Session volume
2.36M
Avg 1.57M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.57%
-5.5%
1M
-3.21%
-4.4%
3M
-8.78%
-13.3%
6M
+8.65%
-9.5%
YTD
+2.97%
-11.3%
1Y
-20.28%
-36.7%
3Y
+18.97%
-63.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CRSP open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+23.29K
Net buying
Buy transactions
4
51.15K shares
Sell transactions
3
27.86K shares
Net transactions
+7
Buys less sells
Sell : buy shares
0.5 : 1
Mixed
Insider-held shares
5.70M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 22, 26 | KASINGER JAMES R. General Counsel |
SELL | 10.40K | $626.46K | Direct |
| Sep 22, 26 | KASINGER JAMES R. General Counsel |
CONVERSION | 10.40K | $141.65K | Direct |
| Sep 17, 26 | BEHBAHANI ALI Director |
SELL | 13.68K | $780.93K | Direct |
| Sep 17, 26 | BEHBAHANI ALI Director |
CONVERSION | 30.00K | $420.00K | Direct |
| Aug 7, 26 | PRASAD RAJU Chief Financial Officer |
STOCK | 750 | $0 | Direct |
| May 29, 26 | PATEL NAIMISH Officer |
SELL | 3.79K | $210.58K | Direct |
| May 28, 26 | PATEL NAIMISH Officer |
— | 10.00K | — | Direct |
| Mar 23, 26 | PRASAD RAJU Chief Financial Officer |
SELL | 3.71K | $173.46K | Direct |
| Mar 23, 26 | KULKARNI SAMARTH Chief Executive Officer |
SELL | 10.02K | $468.74K | Direct |
| Mar 23, 26 | KASINGER JAMES R. General Counsel |
SELL | 3.18K | $148.85K | Direct |
| Mar 20, 26 | KASINGER JAMES R. General Counsel |
— | 6.25K | — | Direct |
| Mar 20, 26 | PRASAD RAJU Chief Financial Officer |
— | 6.25K | — | Direct |
| Mar 20, 26 | KULKARNI SAMARTH Chief Executive Officer |
— | 19.69K | — | Direct |
| Mar 16, 26 | PRASAD RAJU Chief Financial Officer |
STOCK | 750 | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BEHBAHANI ALI |
Director | 16.67K | Sale |
BRUNO JULIANNE |
Chief Operating Officer | 17.63K | Sale |
GEORGE SIMEON J. |
Director | — | Purchase |
GREENE JOHN THOMAS |
Director | 7.00K | Purchase |
KASINGER JAMES R. |
General Counsel | 94.78K | Sale |
KULKARNI SAMARTH |
Chief Executive Officer | 255.50K | Sale |
PATEL NAIMISH |
Officer | 19.36K | Sale |
PRASAD RAJU |
Chief Financial Officer | 14.81K | Stock Gift |
TRECO DOUGLAS A |
Director | 22.00K | Purchase |
Fundamentals
Market cap$5.22B
Enterprise value$3.64B
Revenue (TTM)$13.39M
Gross profit$-461.80M
EBITDA$-513.17M
Net income$-451.14M
EPS (TTM)$-4.46
Free cash flow$-215.85M
Total cash$2.36B
Total debt$783.75M
Book value / share$18.07
Shares outstanding96.69M
Float96.26M
Short % of float22.58%
Dividend yield0.00%
Beta (5Y)1.76
Valuation & profitability ratios
Trailing P/E—
Forward P/E-15.44
PEG ratio—
Price / sales—
Price / book2.99
EV / revenue271.86
EV / EBITDA-7.10
Gross margin0.00%
Operating margin-1127.55%
Profit margin0.00%
Return on equity-26.10%
Return on assets-14.20%
Debt / equity44.87
Current ratio17.85
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $35.00M | $370.00M | $436.00K | -100.0% |
| Operating revenue | $0 | $35.00M | $370.00M | $436.00K | -100.0% |
| Cost of revenue | $213.48M | $120.67M | $130.25M | $110.25M | +76.9% |
| Gross profit | -$213.48M | -$85.67M | $239.75M | -$109.81M | -149.2% |
| Research & development | $381.06M | $310.24M | $387.33M | $461.64M | +22.8% |
| Selling, general & admin | $73.54M | $72.98M | $76.16M | $102.46M | +0.8% |
| Total operating expense | $451.09M | $380.90M | $462.29M | $563.35M | +18.4% |
| Operating income | -$664.57M | -$466.57M | -$222.54M | -$673.16M | -42.4% |
| Pre-tax income | -$577.97M | -$362.67M | -$150.72M | -$650.50M | -59.4% |
| Tax provision | $3.63M | $3.59M | $2.89M | -$325.00K | +1.3% |
| Net income | -$581.60M | -$366.25M | -$153.61M | -$650.17M | -58.8% |
| Net income to common | -$581.60M | -$366.25M | -$153.61M | -$650.17M | -58.8% |
| Basic EPS | -6.47 | -4.34 | -1.94 | -8.36 | -49.1% |
| Diluted EPS | -6.47 | -4.34 | -1.94 | -8.36 | -49.1% |
| EBIT | -$664.57M | -$466.57M | -$222.54M | -$673.16M | -42.4% |
| EBITDA | -$645.09M | -$447.31M | -$202.70M | -$648.99M | -44.2% |
| Basic shares | 89.93M | 84.36M | 79.22M | 77.75M | +6.6% |
| Diluted shares | 89.93M | 84.36M | 79.22M | 77.75M | +6.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $347.56M | $298.26M | $389.48M | $211.88M | — | +16.5% |
| Cash & short-term investments | $1.98B | $1.90B | $1.69B | $1.82B | — | +3.8% |
| Accounts receivable | $0 | $25.00M | $200.00M | $0 | — | -100.0% |
| Total current assets | $1.99B | $1.94B | $1.91B | $1.85B | — | +2.5% |
| Property, plant & equipment | $247.57M | $277.55M | $305.94M | $320.56M | — | -10.8% |
| Goodwill & intangibles | — | $0 | $16.00K | $71.00K | $125.00K | — |
| Total assets | $2.27B | $2.24B | $2.23B | $2.24B | — | +1.0% |
| Total current liabilities | $149.12M | $87.78M | $108.79M | $121.11M | — | +69.9% |
| Total debt | $206.75M | $223.69M | $238.63M | $244.02M | — | -7.6% |
| Total liabilities | $343.43M | $309.95M | $346.77M | $367.58M | — | +10.8% |
| Retained earnings | -$1.95B | -$1.37B | -$999.70M | -$846.09M | — | -42.6% |
| Shareholder equity | $1.92B | $1.93B | $1.88B | $1.88B | — | -0.5% |
| Working capital | $1.84B | $1.85B | $1.80B | $1.73B | — | -0.7% |
| Net tangible assets | $1.92B | $1.93B | $1.88B | $1.88B | — | -0.5% |
| Shares issued | 96.01M | 85.91M | 80.21M | 78.69M | — | +11.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$581.60M | -$366.25M | -$153.61M | -$650.17M | -58.8% |
| Depreciation & amortisation | $19.48M | $19.26M | $19.84M | $24.17M | +1.1% |
| Stock-based compensation | $72.50M | $86.57M | $81.03M | $97.95M | -16.3% |
| Change in working capital | $71.88M | $156.27M | -$193.59M | $19.84M | -54.0% |
| Operating cash flow | -$345.01M | -$142.77M | -$260.38M | -$495.74M | -141.7% |
| Capital expenditure | -$25.91M | -$1.90M | -$11.97M | -$37.19M | -1,263.2% |
| Investing cash flow | -$31.80M | -$280.48M | $374.65M | -$258.65M | +88.7% |
| Financing cash flow | $426.03M | $331.98M | $62.66M | $38.59M | +28.3% |
| Free cash flow | -$370.93M | -$144.68M | -$272.35M | -$532.93M | -156.4% |
| End cash position | $359.08M | $309.78M | $401.07M | $224.06M | +15.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $10.00M | $1.00M | $0 | $0 | $0 | +900.0% |
| Operating revenue | $10.00M | $1.00M | $0 | $0 | $0 | +900.0% |
| Cost of revenue | $40.27M | $45.95M | $53.70M | $57.12M | $45.15M | -12.4% |
| Gross profit | -$30.27M | -$44.95M | -$53.70M | -$57.12M | -$45.15M | +32.7% |
| Research & development | $69.63M | $68.57M | $83.53M | $58.90M | $166.15M | +1.5% |
| Selling, general & admin | $17.55M | $17.18M | $18.40M | $16.93M | $18.92M | +2.2% |
| Total operating expense | $87.00M | $85.30M | $101.06M | $74.94M | $184.17M | +2.0% |
| Operating income | -$117.27M | -$130.25M | -$154.76M | -$132.06M | -$229.32M | +10.0% |
| Pre-tax income | -$90.19M | -$122.09M | -$130.00M | -$105.82M | -$207.26M | +26.1% |
| Tax provision | $960.00K | $839.00K | $614.00K | $619.00K | $1.29M | +14.4% |
| Net income | -$91.15M | -$122.93M | -$130.61M | -$106.44M | -$208.55M | +25.8% |
| Net income to common | -$91.15M | -$122.93M | -$130.61M | -$106.44M | -$208.55M | +25.8% |
| Basic EPS | -0.94 | -1.28 | -1.37 | -1.17 | -2.40 | +26.6% |
| Diluted EPS | -0.94 | -1.28 | -1.37 | -1.17 | -2.40 | +26.6% |
| EBIT | -$117.27M | -$130.25M | -$154.76M | -$132.06M | -$229.32M | +10.0% |
| EBITDA | -$112.99M | -$125.93M | -$149.10M | -$127.63M | -$224.68M | +10.3% |
| Basic shares | 96.51M | 96.05M | 95.27M | 91.31M | 87.07M | +0.5% |
| Diluted shares | 96.51M | 96.05M | 95.27M | 91.31M | 87.07M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $291.34M | $423.31M | $347.56M | $286.50M | $193.62M | — | -31.2% |
| Cash & short-term investments | $2.36B | $2.44B | $1.98B | $1.92B | $1.72B | — | -3.2% |
| Accounts receivable | — | — | $0 | $0 | $0 | $0 | — |
| Total current assets | $2.37B | $2.45B | $1.99B | $1.93B | $1.73B | — | -3.1% |
| Property, plant & equipment | $233.66M | $240.85M | $247.57M | $255.49M | $262.57M | — | -3.0% |
| Total assets | $2.65B | $2.73B | $2.27B | $2.25B | $2.03B | — | -2.8% |
| Total current liabilities | $132.90M | $136.29M | $149.12M | $118.96M | $104.36M | — | -2.5% |
| Long-term debt | $586.20M | $585.47M | — | — | — | — | +0.1% |
| Total debt | $783.75M | $787.64M | $206.75M | $211.02M | $215.45M | — | -0.5% |
| Total liabilities | $904.22M | $911.26M | $343.43M | $329.33M | $318.59M | — | -0.8% |
| Retained earnings | -$2.16B | -$2.07B | -$1.95B | -$1.82B | -$1.71B | — | -4.4% |
| Shareholder equity | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | — | -3.7% |
| Working capital | $2.24B | $2.31B | $1.84B | $1.81B | $1.63B | — | -3.2% |
| Net tangible assets | $1.75B | $1.81B | $1.92B | $1.92B | $1.71B | — | -3.7% |
| Shares issued | 96.66M | 96.50M | 96.01M | 94.00M | 88.55M | — | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$91.15M | -$122.93M | -$130.61M | -$106.44M | -$208.55M | +25.8% |
| Depreciation & amortisation | $4.28M | $4.32M | $5.66M | $4.43M | $4.65M | -0.9% |
| Stock-based compensation | $17.32M | $16.32M | $18.08M | $16.60M | $17.61M | +6.1% |
| Change in working capital | -$3.70M | -$15.41M | $22.64M | $10.91M | -$16.51M | +76.0% |
| Operating cash flow | -$83.50M | -$108.90M | -$92.55M | -$84.63M | -$113.88M | +23.3% |
| Capital expenditure | -$3.12M | -$504.00K | -$517.00K | -$74.00K | -$25.12M | -519.2% |
| Investing cash flow | -$55.66M | -$410.74M | $37.20M | -$119.23M | $69.98M | +86.4% |
| Financing cash flow | $7.18M | $591.91M | $116.41M | $296.77M | $2.26M | -98.8% |
| Free cash flow | -$86.62M | -$109.40M | -$93.07M | -$84.71M | -$139.00M | +20.8% |
| End cash position | $299.34M | $431.31M | $359.08M | $298.02M | $205.14M | -30.6% |
Options analytics
Put / call volume
0.49
Call-heavy session
Put / call open interest
0.48
Positioning, not flow
Max pain
55.00
+1.9% from spot
ATM implied vol
92.2%
Nearest strike to spot
Skew (10% OTM)
-8.6%
Calls bid over puts
Call volume
832
Contracts, this expiry
Put volume
408
Contracts, this expiry
Heaviest call OI
60.00
331 contracts
Heaviest put OI
55.00
263 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.18 | -0.94 | +20.6% |
| Mar 2026 | -1.23 | -1.28 | -3.7% |
| Dec 2025 | -1.23 | -1.37 | -11.7% |
| Sep 2025 | -1.29 | -1.17 | +9.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.05 | 17 | $16.54M | +1,760.0% |
| Next quarter | -1.16 | 17 | $16.35M | +1,792.9% |
| Current year | -4.45 | 18 | $40.83M | +1,063.3% |
| Next year | -3.50 | 18 | $156.58M | +283.5% |
Analyst targets & ownership
Mean target$87.56
High target$291.00
Low target$44.00
Implied upside62.14%
Analyst count18
ConsensusBUY
Strong buy / Buy5 / 8
Hold9
Sell / Strong sell0 / 0
Held by insiders5.89%
Held by institutions78.19%
Institutions holding679
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
55.33
-2.41% from price
SMA 20
54.95
-1.73% from price
SMA 50
54.73
-1.34% from price
SMA 100
53.51
+0.92% from price
SMA 200
53.29
+1.34% from price
EMA 12
55.46
-2.63% from price
EMA 26
55.34
-2.41% from price
EMA 50
54.82
-1.50% from price
RSI (14)
46.2
Neutral
MACD (12,26,9)
0.12
Hist -0.08
ATR (14)
3.56
6.59% of price
Realised vol 30D
49.2%
Annualised
Bollinger upper
59.15
20, 2σ
Bollinger lower
50.75
20, 2σ
50 / 200 cross
Golden
54.73 vs 53.29
Trend bias
Above 200
+1.34%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.78
More volatile than market
Correlation to SPY
0.39
Loosely linked
Realised vol 30D
49.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-42.3%
Peak to trough
Max drawdown 5Y
-69.6%
Peak to trough
ATR 14
3.56
6.59% of price
Beta (reported)
1.76
5Y monthly, from filing
Short interest
Shares short
19.07M
Prior 18.74M
Change vs prior
+1.7%
Shorts adding
% of float
22.58%
Heavily shorted
% of shares out
19.72%
Against total outstanding
Days to cover
12.8
Crowded exit
Float
96.26M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 31, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Aug 31, 26 | Needham | MAINTAINED | Buy | Buy |
| Aug 25, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| Aug 4, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Jul 8, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 6, 26 | Citizens | MAINTAINED | Market Outperform | Market Outperform |
| May 13, 26 | Bernstein | MAINTAINED | Market Perform | Market Perform |
| May 6, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Mar 17, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Feb 17, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Feb 13, 26 | TD Cowen | MAINTAINED | Hold | Hold |
| Feb 13, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-03
Offering Registrations
S-8 · 2026-06-05
Corporate Changes & Voting Matters
8-K · 2026-06-04
Periodic Financial Reports
10-Q · 2026-05-04
Annual Report to Shareholders
ARS · 2026-04-21
Proxy Statements
PRE 14A · 2026-04-02
Corporate Changes & Voting Matters
8-K · 2026-03-16
Corporate Changes & Voting Matters
8-K · 2026-03-11
Headlines
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
Zacks · 6h ago
Wall Street Bulls Look Optimistic About CRISPR Therapeutics (CRSP): Should You Buy?
Zacks · 2d ago
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
GlobeNewswire · 5d ago
Anthropic Just Made a CRISPR-Like Discovery. What It Actually Means for CRSP Stock Investors.
Barchart · 7d ago
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
Barchart · 8d ago
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Zacks · 8d ago
CRISPR Therapeutics Has 2 Key Catalysts Coming by the End of 2026. Is the Market Underestimating Them?
Motley Fool · 8d ago
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
Zacks · 11d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.